<div id="readability-page-1"><div><ul> <li>10% owner Opaleye Management recently sold nearly 200,000 Harrow shares shortly after the latest earnings release.</li> <li>The transaction was an indirect insider sale, but Opaleye still holds close to a 10% stake in Harrow.</li> <li>The sale follows a period of increased share price volatility and draws attention to insider activity at NasdaqGM:HROW.</li> </ul> <p>Harrow, traded on NasdaqGM:HROW, recently closed at $35.38 after a 33.0% decline over the past month and a 29.1% decline year to date. Even with this pullback, the stock shows a 26.9% gain over the past year and a very large increase over five years, so many holders are still sitting on sizeable long-term gains.</p> <p>For investors, a key question is how to interpret a large insider sale that still leaves Opaleye with a substantial position. Insider moves like this are often one input among many, considered alongside fundamentals, balance sheet strength and individual risk tolerance, rather than a stand-alone signal about what may happen next.</p> <p>Stay updated on the most important news stories for Harrow by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Harrow.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aab17550-e396-4149-bdca-440135e903d3/chart/quote-price/query-ZGF0ZT0yMDI2LTAzLTI3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aab17550-e396-4149-bdca-440135e903d3/chart/quote-price/query-ZGF0ZT0yMDI2LTAzLTI3"/><figcaption>NasdaqGM:HROW 1-Year Stock Price Chart</figcaption></figure> <p>See which insiders are buying and buying and selling Harrow following this latest news.</p> <p>Opaleye Management’s US$7.8m sale, coming right after a wide Q4 2025 earnings miss and a sharp share price move, is likely to catch the eye because it combines timing around disappointing results with Harrow’s decision to fund its plans using higher coupon debt. The fund still holds roughly 3.7m shares, close to a 10% stake, so this looks more like portfolio sizing than a full vote of no confidence. For you as a shareholder or potential buyer, the signal is mixed: a large, long term holder is reducing exposure after a weak quarter, while the company is committing to a higher fixed interest burden through US$50m of 8.625% senior unsecured notes due 2030 rather than issuing equity.</p> <h3>How This Fits Into The Harrow Narrative</h3> <ul> <li>The additional 2030 notes provide funding for launches and product development that align directly with the growth story around VEVYE, IHEEZO, TRIESENCE and newer assets.</li> <li>The combination of an earnings miss and a sizeable insider sale underlines execution risk in turning strong revenue expectations into consistent profitability.</li> <li>The narrative focuses heavily on product growth and margin expansion, while this fresh layer of unsecured debt and insider profit taking may not be fully reflected in assumptions about balance sheet risk and shareholder behavior.</li> </ul> <p>Knowing what a company is worth starts with understanding its story.                         Check out one of the top narratives in the Simply Wall St Community for Harrow to help decide what it's worth to you.</p> <h3>The Risks and Rewards Investors Should Consider</h3> <ul> <li>⚠️ A 10% holder trimming nearly 200,000 shares following an earnings miss can suggest reduced risk tolerance for short term volatility.</li> <li>⚠️ The new 8.625% senior unsecured notes add fixed interest costs that increase sensitivity to any slowdown in expected product uptake or pricing pressure.</li> <li>🎁 Opaleye’s remaining near 10% position indicates continued exposure to Harrow’s long term story rather than a full exit.</li> <li>🎁 Using debt instead of new equity avoids immediate dilution for existing shareholders while funding product launches and potential business development.</li> </ul> <h3>What To Watch Going Forward</h3> <p>From here, the key things to watch are whether Harrow’s next few quarters show progress on converting its ophthalmic pipeline into cash flow that comfortably covers interest on the 2030 notes, and how other insiders behave. Keep an eye on further Form 4 filings, any changes in guidance tied to the use of debt proceeds, and how the market responds if execution on key products like VEVYE or TRIESENCE falls short of expectations. It can also be useful to compare Harrow’s insider and capital allocation trends with peers such as Alcon, Bausch + Lomb or Ocular Therapeutix to see how risk and reward stack up.</p> <p>To ensure you're always in the loop on how the latest news impacts the investment narrative for Harrow, head to the                         community page for Harrow to never miss an update on the top community narratives.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if Harrow might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

ARKG

<p>Opaleye Management sold nearly 200,000 shares of Harrow after a disappointing earnings report, reducing its stake to close to 10%. Despite a recent 33% decline in share price, Harrow's stock has gained 26.9% over the past year. The sale, combined with the issuance of $50 million in high-interest debt, raises concerns about execution risk and profitability. Investors should monitor Harrow's ability to convert its product pipeline into cash flow and watch insider trading activity for further insights.</p>

Simplywall

VanEck Biotech ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Harrow Health Pref Share HROWL 8.625 04/30/26

iShares Global Healthcare

VG Health

First Trust NYSE Arca Biotech Index Fd

SPDR Pharmac

Direxion S&P Biotech Bull 3X

Harrow

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

iShares US Pharma

Health Care Select Sector SPDR

Harrow Health Pref Share HROWM 11.875 12/31/27

ALPS Medical Breakthrough

Opaleye Trims Harrow Stake After Earnings Miss While Debt Risk Rises